For Adverse Effects and Safety Monitoring of Anti-Epileptic Drugs, use the highest-yield facts to drive concrete treatment decisions. Pay particular attention to Topiramate: weak carbonic anhydrase inhibitor → kidney stones (avoid with acetazolamide/ketogenic diet), Oxcarbazepine: hyponatremia more common than carbamazepine, onset within 3 months, and Felbamate: restricted due to aplastic anemia/hepatic failure risk when choosing therapy, counseling about risk, planning monitoring, and deciding when closer follow-up or escalation is needed.

Topiramate: weak carbonic anhydrase inhibitor → kidney stones (avoid with acetazolamide/ketogenic diet)Oxcarbazepine: hyponatremia more common than carbamazepine, onset within 3 monthsFelbamate: restricted due to aplastic anemia/hepatic failure riskHLA B-15-02 allele carriers: high carbamazepine Stevens-Johnson syndrome riskPhenobarbital/benzodiazepines: cognitive side effects (psychomotor slowing, reduced attention)